Siemens Healthineers AG (ETR:SHL) Annual Results: Here's What Analysts Are Forecasting For This Year

It's been a good week for Siemens Healthineers AG (ETR:SHL) shareholders, because the company has just released its latest full-year results, and the shares gained 3.5% to €42.74. It looks like the results were a bit of a negative overall. While revenues of €23b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 4.6% to hit €1.91 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the consensus forecast from Siemens Healthineers' 18 analysts is for revenues of €24.2b in 2026. This reflects a modest 3.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 9.5% to €2.10. Before this earnings report, the analysts had been forecasting revenues of €24.2b and earnings per share (EPS) of €2.10 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

Check out our latest analysis for Siemens Healthineers

There were no changes to revenue or earnings estimates or the price target of €57.67, suggesting that the company has met expectations in its recent result. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Siemens Healthineers analyst has a price target of €65.00 per share, while the most pessimistic values it at €48.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. We would highlight that Siemens Healthineers' revenue growth is expected to slow, with the forecast 3.6% annualised growth rate until the end of 2026 being well below the historical 8.2% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 5.7% per year. Factoring in the forecast slowdown in growth, it seems obvious that Siemens Healthineers is also expected to grow slower than other industry participants.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at €57.67, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Siemens Healthineers. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Siemens Healthineers analysts - going out to 2028, and you can see them free on our platform here.

And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.